Literature DB >> 29050400

Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.

Julia C Fitzgerald1, Alexander Zimprich2, Daniel A Carvajal Berrio3, Kevin M Schindler1,4, Brigitte Maurer1, Claudia Schulte1, Christine Bus1, Anne-Kathrin Hauser1, Manuela Kübler1, Rahel Lewin1, Dheeraj Reddy Bobbili5, Lisa M Schwarz1,6, Evangelia Vartholomaiou7, Kathrin Brockmann1, Richard Wüst1,8, Johannes Madlung9, Alfred Nordheim10, Olaf Riess11, L Miguel Martins12, Enrico Glaab5, Patrick May5, Katja Schenke-Layland3,13,14, Didier Picard7, Manu Sharma15, Thomas Gasser1, Rejko Krüger1,5,16.   

Abstract

The mitochondrial proteins TRAP1 and HTRA2 have previously been shown to be phosphorylated in the presence of the Parkinson's disease kinase PINK1 but the downstream signalling is unknown. HTRA2 and PINK1 loss of function causes parkinsonism in humans and animals. Here, we identified TRAP1 as an interactor of HTRA2 using an unbiased mass spectrometry approach. In our human cell models, TRAP1 overexpression is protective, rescuing HTRA2 and PINK1-associated mitochondrial dysfunction and suggesting that TRAP1 acts downstream of HTRA2 and PINK1. HTRA2 regulates TRAP1 protein levels, but TRAP1 is not a direct target of HTRA2 protease activity. Following genetic screening of Parkinson's disease patients and healthy controls, we also report the first TRAP1 mutation leading to complete loss of functional protein in a patient with late onset Parkinson's disease. Analysis of fibroblasts derived from the patient reveal that oxygen consumption, ATP output and reactive oxygen species are increased compared to healthy individuals. This is coupled with an increased pool of free NADH, increased mitochondrial biogenesis, triggering of the mitochondrial unfolded protein response, loss of mitochondrial membrane potential and sensitivity to mitochondrial removal and apoptosis. These data highlight the role of TRAP1 in the regulation of energy metabolism and mitochondrial quality control. Interestingly, the diabetes drug metformin reverses mutation-associated alterations on energy metabolism, mitochondrial biogenesis and restores mitochondrial membrane potential. In summary, our data show that TRAP1 acts downstream of PINK1 and HTRA2 for mitochondrial fine tuning, whereas TRAP1 loss of function leads to reduced control of energy metabolism, ultimately impacting mitochondrial membrane potential. These findings offer new insight into mitochondrial pathologies in Parkinson's disease and provide new prospects for targeted therapies.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Parkinson’s disease; experimental models; metabolic disease; mitochondrial diseases; neuroprotection

Mesh:

Substances:

Year:  2017        PMID: 29050400     DOI: 10.1093/brain/awx202

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  36 in total

1.  Biallelic loss of EEF1D function links heat shock response pathway to autosomal recessive intellectual disability.

Authors:  Sibel Aylin Ugur Iseri; Emrah Yucesan; Feyza Nur Tuncer; Mustafa Calik; Yesim Kesim; Gunes Altiokka Uzun; Ugur Ozbek
Journal:  J Hum Genet       Date:  2019-02-21       Impact factor: 3.172

Review 2.  Mitochondrial proteostasis in the context of cellular and organismal health and aging.

Authors:  Erica A Moehle; Koning Shen; Andrew Dillin
Journal:  J Biol Chem       Date:  2018-04-05       Impact factor: 5.157

Review 3.  Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source.

Authors:  Jiacheng Ma; Annemieke Kavelaars; Patrick M Dougherty; Cobi J Heijnen
Journal:  Cancer       Date:  2018-02-20       Impact factor: 6.860

Review 4.  NAD+ in Brain Aging and Neurodegenerative Disorders.

Authors:  Sofie Lautrup; David A Sinclair; Mark P Mattson; Evandro F Fang
Journal:  Cell Metab       Date:  2019-10-01       Impact factor: 27.287

Review 5.  TRAP1 Chaperones the Metabolic Switch in Cancer.

Authors:  Laura A Wengert; Sarah J Backe; Dimitra Bourboulia; Mehdi Mollapour; Mark R Woodford
Journal:  Biomolecules       Date:  2022-06-04

6.  Acute Administration of Metformin Protects Against Neuronal Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury via Regulation of the AMPK/CREB/BDNF Pathway.

Authors:  Ke Liu; Lulu Li; Zhijun Liu; Gang Li; Yanqing Wu; Xingjun Jiang; Mengdie Wang; Yanmin Chang; Tingting Jiang; Jianheng Luo; Jiahui Zhu; Hongge Li; Yong Wang
Journal:  Front Pharmacol       Date:  2022-04-01       Impact factor: 5.988

Review 7.  Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease.

Authors:  Sandra Franco-Iborra; Miquel Vila; Celine Perier
Journal:  Front Neurosci       Date:  2018-05-23       Impact factor: 4.677

8.  Honokiol Bis-Dichloroacetate Is a Selective Allosteric Inhibitor of the Mitochondrial Chaperone TRAP1.

Authors:  Carlos Sanchez-Martin; Daniela Menon; Elisabetta Moroni; Mariarosaria Ferraro; Ionica Masgras; Justin Elsey; Jack L Arbiser; Giorgio Colombo; Andrea Rasola
Journal:  Antioxid Redox Signal       Date:  2020-06-23       Impact factor: 8.401

9.  No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease.

Authors:  Johannes J Gaare; Gonzalo S Nido; Pawel Sztromwasser; Per M Knappskog; Olav Dahl; Morten Lund-Johansen; Guido Alves; Ole-Bjørn Tysnes; Stefan Johansson; Kristoffer Haugarvoll; Charalampos Tzoulis
Journal:  Brain       Date:  2018-03-01       Impact factor: 13.501

10.  Commentary: Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.

Authors:  Sachchida N Rai; Saumitra S Singh; Hareram Birla; Walia Zahra; Aaina S Rathore; Payal Singh; Surya P Singh
Journal:  Front Aging Neurosci       Date:  2018-07-31       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.